Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases
The company has received five final approvals
According to Sun Pharma, the purpose of the strategic investment is to obtain access to the technology for certain compounds and territories while also fostering the development of novel pharmaceutical delivery systems.
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
The product is expected to be launched in December 2023
US FDA approval based on NEURO-TTRansform Phase III results
BioVaxys has been granted exclusivity while the parties work in good faith on the drafting of a definitive agreement
Astellas has acquired abiraterone decanoate being developed by Propella to treat prostate cancer
The plant is yet to start commercial operations
Subscribe To Our Newsletter & Stay Updated
